M25-288 Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Advanced or Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288 (AndroMETa-PDAC-288)

Principal Investigator

Prof Mark Middleton

Contact us

Email: orh-tr.earlyphasenurses@nhs.net

IRAS number

1013191